An observational study in Arrhythmia, sponsored by Medtronic Cardiac Ablation Solutions. Active, not recruiting at 21 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Arrhythmias, Cardiac by Medtronic — 4 open to participants now, 6 under way, none of them phase 3. Arrhythmias, Cardiac · Medtronic.
Among the 40 studies in Arrhythmias, Cardiac by Medtronic, this one is the 10th largest by planned enrollment of the 23 observational ones that give a count, is the only one that started in 2021, is one of 23 observational ones, and was the 35th registered.
1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 235 are open to participants now.
Browse Arrhythmias, Cardiac studies →4 of the 40 studies in Arrhythmias, Cardiac by Medtronic are open now, in 12 countries. Recruiting first, the newest first:
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
Medtronic · Sites in United States, Australia, Austria and 32 more countries
Medtronic Cardiac Ablation Solutions
Ages 18–80
By country, each count listing its studies:
Of the 166 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 545 is above the median of 200 across 467 observational studies indexed under Arrhythmias, Cardiac.
Median enrollment 320 across the 17 interventional studies, 370 across the 23 observational. Of the 33 that completed or were terminated, 15 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic Cardiac Ablation Solutions, one of the names counted as Medtronic. Under that name alone:
Medtronic Cardiac Ablation Solutions is the lead sponsor of 37 studies on the registry; 9 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 8 (100%) have results posted.
2 of the studies in Arrhythmias, Cardiac by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
| NCT04735016Medtronic Cardiac Ablation SolutionsDiamondTemp Global Registry | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Arrhythmias, Cardiac by Medtronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The DiamondTemp™ Global Registry is a prospective, global, multi-center, observational post-market registry.
The DiamondTemp™ Global Registry is a prospective, global, multi-center, observational post-market registry. The purpose of this clinical study is to describe clinical performance and safety data in a broad patient population treated with the commercially available DiamondTemp™ Family of Cardiac Ablation Catheters (hereafter referred to as the DiamondTemp™ Ablation System) and followed according to the standard of care at each respective institution. The follow up period is intended to align with standard practice and subjects will be followed for a minimum of 12 months post-procedure.
Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for an ablation with the DiamondTemp™ Ablation System may be approached regarding enrollment in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients enrolled and treated with the DiamondTemp™ Ablation System
Device: DiamondTemp™ Ablation System
A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
Freedom from Recurrence at 12 Months
Estimate the 12-month freedom from recurrence of the arrhythmia(s) treated at the study index ablation procedure using the DiamondTemp™ Ablation System.
Time frame: 12 Months
Freedom from Device / Procedure Related Adverse Events
Estimate serious device and serious procedure-related adverse events for ablation using the DiamondTemp™ Ablation System through 12 months.
Time frame: 12 Months
Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.
Of 69 industry-sponsored observational studies under Arrhythmias, Cardiac, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 68 months is above that.
Counting every sponsor, half of 259 studies reached it within 38 months; a quarter within 16 and three quarters within 97.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2031 → Dec 2026 and completion Mar 2031 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Cardiac Ablation Solutions →